CDKN2AIP Activators
CDKN2AIP activators pivot around modulating the cell cycle, cellular senescence, and DNA damage response. Agents such as Forskolin, by influencing cAMP levels, and CDK inhibitors like Olomoucine and Roscovitine provide a framework for potential CDKN2AIP modulation by influencing cell cycle progression. DNA damage inducers, such as Etoposide and Cisplatin, underscore the tight link between DNA integrity and the regulation of proteins like CDKN2AIP, which can come into play upon DNA insult.
Lovastatin, while primarily known for its cholesterol-lowering ability, delves into cell cycle regulation by inhibiting HMG-CoA reductase, and thus may indirectly modulate CDKN2AIP. Similarly, Genistein, a phytoestrogen, traverses a myriad of cellular pathways, including cell cycle regulation, which can put CDKN2AIP in its purview. Microtubule modulators, Nocodazole, which disrupts, and Paclitaxel, which stabilizes, bring forth the importance of cytoskeletal integrity in maintaining cell cycle progression and the potential involvement of CDKN2AIP therein. Sulforaphane, another compound that induces cell cycle arrest, reinforces the prominence of CDKN2AIP in the intricate cell cycle landscape, emphasizing its indirect activation upon the modulation of various cell cycle checkpoints and related pathways.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
By elevating cAMP levels, it influences cell cycle progression and can indirectly modulate CDKN2AIP. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
A CDK inhibitor that can potentially affect the cell cycle, thereby influencing CDKN2AIP. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Induces DNA damage and cell cycle arrest, possibly leading to CDKN2AIP activation. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Can induce DNA damage, possibly leading to the involvement of CDKN2AIP in the cell cycle. | ||||||
L-Mimosine | 500-44-7 | sc-201536A sc-201536B sc-201536 sc-201536C | 25 mg 100 mg 500 mg 1 g | $36.00 $88.00 $220.00 $436.00 | 8 | |
Causes cell cycle arrest in G1 phase, potentially affecting CDKN2AIP. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
A CDK inhibitor that influences cell cycle progression and might indirectly modulate CDKN2AIP. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $29.00 $90.00 $339.00 | 12 | |
By inhibiting HMG-CoA reductase, it can induce cell cycle arrest, influencing CDKN2AIP indirectly. | ||||||
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $78.00 $260.00 | 18 | |
Induces DNA damage and cell cycle arrest, potentially influencing CDKN2AIP. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Influences various cellular pathways, including cell cycle progression, possibly affecting CDKN2AIP indirectly. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Disrupts microtubules, leading to cell cycle arrest, which might influence CDKN2AIP. | ||||||